February 22, 2017 11:51 AM ET

Pharmaceuticals

Company Overview of Taiho Pharmaceutical Co., Ltd.

Company Overview

Taiho Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products for customers worldwide. Its products include S-1, an oral antimetabolite and a combination of pharmacological compounds; ABI-007(Abraxane, a human serum albumin-bound paclitaxel; TSU-68, an orally administered, small-molecule, multiple receptor tyrosine kinase inhibitor; TAS-102, a novel combination antitumor agent; TAS-118, an antimetabolite solution; and ET-743(trabectedine), a synthetic derivative of a substance extracted from the colonial tunicate ecteinascidia turbinata. Its products also comprise TAS-114, an inhibitor of dUTPase, a gatekeeper protein in pyrimidine-metabolism; TAS-115, ...

1-27 Kandanishiki-cho

Chiyoda-ku

Tokyo,  101-8444

Japan

Founded in 1963

Phone:

81 3 3294 4527

Fax:

81 3 3233 4057

Key Executives for Taiho Pharmaceutical Co., Ltd.

President and Representative Director
Chief Executive Officer of Otsuka Holdings Co., Ltd., President of Otsuka Holdings Co., Ltd. and Representative Director of Otsuka Holdings Co., Ltd.
Age: 66
Head of Production Division - Cmc Center and Director
Compensation as of Fiscal Year 2016.

Taiho Pharmaceutical Co., Ltd. Key Developments

X-Chem, Inc. Announces Multi-Target Drug Discovery Collaboration with Taiho Pharmaceutical Using DEX Technology

X-Chem, Inc. announced that it entered into a multi-target drug discovery collaboration with Taiho Pharmaceutical Co. Ltd. This collaboration will grant Taiho access to X-Chem’s DEX™ technology which is based on DNA-encoded libraries of small molecules with more than 120 billion molecules. The aim of the collaboration is to discover innovative lead structures for complex drug targets in multiple therapeutic areas with unmet medical need. Under the terms of this new agreement, X-Chem will receive an up-front payment as well as potential pre-clinical, clinical and regulatory milestone payments and sales milestones, up to a total of $352 million. Taiho has an exclusive option to license any programs generated in the course of the collaboration. X-Chem will also receive royalties for each successfully commercialized drug that results from a licensed collaboration program.

Taiho Pharmaceutical Co., Ltd. Announces the Launch of Bilanoa Tablets 20 Mg

Taiho Pharmaceutical Co., Ltd. and Meiji Seika Pharma Co., Ltd. announced the launch of Bilanoa Tablets 20 mg (generic name: bilastine), an oral anti-allergy drug, in Japan. This product is an second-generation anti-histamine product, discovered by Faes Farma S.A. in Spain. Taiho has further developed the drug after signing a license agreement with Faes Farma in July 2012 for the development and marketing rights in Japan. In September 2016, Taiho received approval to manufacture and market the drug for the indications of allergic rhinitis, urticaria, and itching resulting from skin diseases (eczema/dermatitis and cutaneous pruritus). It has been approved in over 100 countries and regions and marketed by several partners under license from Faes Farma for the treatment of allergic rhinitis and urticaria.

Taiho Pharmaceutical Co., Ltd. Announces Establishment of Taiho Ventures, LLC

Taiho Pharmaceutical Co., Ltd. announced on May 10 that it has established Taiho Ventures, LLC, a strategic corporate venture capital arm of TPC, in California, USA. Taiho Ventures will be investing globally in the start-up companies that discover and develop innovative therapeutic products and/or drug-enabling platform technologies that demonstrate a clear potential to benefit cancer patients. With the support of Taiho's established expertise in the field of oncology product discovery and development, Taiho Ventures will provide financial resources and company outreach to build strategic alliances to help translate novel research and high-potential drug candidates into cornerstone products. Initially, Taiho Ventures will make investments from the pooled amount of $50 million.

Similar Private Companies By Industry

Company Name Region
ABsize Inc. Asia
AccuRna, Inc. Asia
ACE Japan, L.L.C. Asia
Advanced Immunotherapy Co., Ltd. Asia
AIP Corporation Asia

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Taiho Pharmaceutical Co., Ltd., please visit www.taiho.co.jp. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.